GSK PLC said Tuesday that it has agreed to buy clinical-stage biopharmaceutical company Affinivax, Inc. for up to $3.3 billion.
The healthcare company
said that it will pay $2.1 billion upfront and up to $1.2 billion in potential development milestones and that the deal is expected to close in the third quarter.
The transaction will provide access to next-generation pneumococcal vaccine candidates and support the development of its vaccines and specialty medicines, GSK said.
Write to Kyle Morris at email@example.com